Across mismatch repair-proficient (MMR-p) metastatic cancers in the Hartwig database25, 36 out of 2,256 (1.6%) cancers had a clonal B2M alteration, which was frequently accompanied by loss of heterozygosity (LOH) (Extended Data Fig. 1h and Supplementary Table 3). This evidence concerns the gene B2M and cancer.